Paper17699786
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
Ogino A and 9 others. Cancer Res, 2007. Cited by 167 papers, by iCite.
Cite this record
ConductScience Library. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Papers, record 17699786. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17699786
- Cell line
- RPC-91 paper
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Cell lines1
Source Cell lines
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| ErbB Receptors | Major topic |
| Lung Neoplasms | Major topic |
| Mutation | Major topic |
| Quinazolines | Major topic |
| Adenocarcinoma | |
| Cell Line, Tumor | |
| Drug Resistance, Neoplasm | |
| Gefitinib | |
| Humans | |
| Phosphorylation | |
| Protein Kinase Inhibitors | |
| Receptor, ErbB-3 |
Source PubMed
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 167 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41599648 | Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41599648 | PubMed |
| 41535280 | EGFR inhibitor-resistant lung cancers exhibit collateral sensitivity to a covalent, cysteine-independent KEAP1 oligomerizing molecular bridge. | Nat Commun | 2026 | https://conductscience.org/library/papers/41535280 | PubMed |
| 41510378 | Targeting ferroptosis to overcome drug resistance in lung cancer. | Transl Lung Cancer Res | 2025 | https://conductscience.org/library/papers/41510378 | PubMed |
| 41222695 | CRISPR screens reveal YAP/TEAD axis as a mediator of drug-tolerant cells in EGFR-mutant NSCLC. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41222695 | PubMed |
| 40323013 | APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/40323013 | PubMed |
| 39138145 | Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39138145 | PubMed |
| 39122703 | Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/39122703 | PubMed |
| 39041204 | Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor-Tolerant Cells in NSCLC Patient-Derived Xenografts. | Cancer Res Commun | 2024 | https://conductscience.org/library/papers/39041204 | PubMed |
| 38658677 | Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer. | Commun Biol | 2024 | https://conductscience.org/library/papers/38658677 | PubMed |
| 37111291 | Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-Present). | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37111291 | PubMed |
| 36028467 | Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment. | Cancer Sci | 2022 | https://conductscience.org/library/papers/36028467 | PubMed |
| 35605028 | APE1 shRNA-loaded cancer stem cell-derived extracellular vesicles reverse Erlotinib resistance in non-small cell lung cancer via the IL-6/STAT3 signalling. | Clin Transl Med | 2022 | https://conductscience.org/library/papers/35605028 | PubMed |
| 35408854 | Hybrid Pharmacophore- and Structure-Based Virtual Screening Pipeline to Identify Novel EGFR Inhibitors That Suppress Non-Small Cell Lung Cancer Cell Growth. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35408854 | PubMed |
| 34830794 | Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34830794 | PubMed |
| 34702990 | Harnessing the predictive power of preclinical models for oncology drug development. | Nat Rev Drug Discov | 2022 | https://conductscience.org/library/papers/34702990 | PubMed |
| 34692766 | ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non-Small-Cell Lung Cancer: A Multi-Center Retrospective Study. | Front Mol Biosci | 2021 | https://conductscience.org/library/papers/34692766 | PubMed |
| 34590051 | A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood. | JTO Clin Res Rep | 2021 | https://conductscience.org/library/papers/34590051 | PubMed |
| 34518338 | Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. | Cold Spring Harb Perspect Med | 2021 | https://conductscience.org/library/papers/34518338 | PubMed |
| 34396444 | Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis. | Mol Med Rep | 2021 | https://conductscience.org/library/papers/34396444 | PubMed |
| 34386061 | Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression. | Oncol Lett | 2021 | https://conductscience.org/library/papers/34386061 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MAPK3 | 5595 | PubTator's text mining | https://conductscience.org/library/genes/5595 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17699786
GET https://conductscience.org/api/papers/v1/17699786/cited_by?page=2